New Investigational Drug May Slow Progression of Breast Cancer

MORGANTOWN, W.Va. – West Virginia University’s Mary Babb Randolph Cancer Center is participating in an expanded access program through GlaxoSmithKline on a new investigational drug that might benefit patients with breast cancer.

“Participating in this program allows us to offer our patients the latest medical advancements available to them,” said Jame Abraham, M.D., medical director of the Cancer Center and head of the Comprehensive Breast Care Center. “Early results are encouraging and we are pleased to participate in research that focuses on one of the most common cancers in our region.”

Lapatinib targets certain cancer cells and attacks them from within, targeting two proteins that are believed to be key to the growth of about one-quarter of breast cancers. It comes in pill form and is taken once a day.  While lapatinib has side effects, most patients are able to tolerate these.

The MBRCC is the only site in West Virginia currently participating in the program.

The expanded access program is currently enrolling patients. Certain criteria must be met for a patient to be eligible.

For more information about the expanded access program, contact Shannon Filburn, study coordinator, at (304) 293-2745.

- WVU -

For more information:
Steve Bovino, HSC News Service, (304) 293-7087

Return To News Releases